Loading...
Loading...
NAMS| Name | Value |
|---|---|
| Revenues | 97.5M |
| Cost of Revenue | 0.0M |
| Gross Profit | 97.5M |
| Operating Expense | -104.5M |
| Operating I/L | 22.4M |
| Other Income/Expense | -0.9M |
| Interest Income | 0.0M |
| Pretax | 21.4M |
| Income Tax Expense | 1.1M |
| Net Income/Loss | 20.4M |
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company specializing in developing innovative treatments for metabolic diseases. Their lead candidate, obicetrapib, is a selective inhibitor targeting the Cholesteryl Ester Transfer Protein (CETP), with proven efficacy in reducing low-density lipoprotein cholesterol (LDL-C) and increasing high-density lipoprotein cholesterol (HDL-C). By focusing on improving patient care in populations with metabolic diseases, the company aims to generate revenue through the successful development and commercialization of their novel therapies.
